Mounjaro (Tirzepatide) Injection Pen – 5 mg

Introduction

The Mounjaro (Tirzepatide) 5 mg Injection Pen is the next step in treatment for adults with type 2 diabetes. After completing the initial 2.5 mg starter dose, most patients advance to the 5 mg pen for ongoing therapy. This stage provides enhanced blood sugar control while supporting meaningful weight management. Developed by Eli Lilly, Mounjaro is the first dual GIP and GLP-1 receptor agonist, offering a unique, innovative approach to metabolic health.

What is Mounjaro 5 mg Used For?

Mounjaro (tirzepatide) is prescribed to:

• Improve glycaemic control in adults with type 2 diabetes.

• Reduce HbA1c levels when diet and exercise alone are not enough.

• Support weight management, which is closely linked to diabetes progression.

The 5 mg strength is typically the first maintenance dose after the starter period, allowing patients to stabilise before moving to higher strengths if required.

How It Works

Mounjaro is the first-in-class “twincretin” therapy, acting on two hormone receptors:

• GLP-1 receptor agonist: increases insulin secretion, slows digestion, and reduces appetite.

• GIP receptor agonist: enhances insulin sensitivity and complements GLP-1 activity.

By combining these pathways, Mounjaro delivers superior blood sugar control and weight reduction compared to standard GLP-1 therapies.

Key Benefits of Mounjaro 5 mg

1. Blood Sugar Regulation

• Stimulates insulin only when blood glucose is high.

• Reduces glucagon, lowering fasting and post-meal glucose.

2. Weight Management

• Helps patients feel full faster.

• Reduces cravings and caloric intake.

3. Cardiometabolic Improvements

• Supports cholesterol reduction.

• Lowers blood pressure and inflammation markers.

4. Weekly Convenience

Each prefilled pen contains a single weekly dose, making it simple to follow your treatment plan.

Dosing and Administration

• Initiation: Treatment starts with 2.5 mg weekly for 4 weeks.

• Maintenance: Patients then move to 5 mg weekly.

• Escalation: If needed, the dose may gradually increase (7.5–15 mg).

How to use:

• Inject subcutaneously into the abdomen, thigh, or upper arm.

• Rotate injection sites weekly.

• Can be taken any time of day, with or without food.

1 pen = 1 dose = 1 week.
For a 1-month supply, patients typically need 4 pens.

Possible Side Effects

Most common:

• Nausea, vomiting, diarrhoea, constipation

• Reduced appetite

Less common but serious:

• Pancreatitis (abdominal pain)

• Gallbladder issues

• Kidney problems due to dehydration

Patients with a personal or family history of medullary thyroid carcinoma or MEN 2 should not use tirzepatide. Always consult your healthcare provider before use.

Storage Instructions

• Keep refrigerated (2°C to 8°C).

• Do not freeze.

• Can be stored at room temperature (below 30°C) for up to 21 days.

• Protect from light, keep in original packaging.

Why Choose the 5 mg Pen?

• Smooth transition from starter dose to active therapy.

• Balances efficacy and tolerability.

• Helps patients see measurable results in both blood sugar and weight loss.

• Designed for ease of use with prefilled, ready-to-inject pens.

Conclusion

The Mounjaro (Tirzepatide) 5 mg Injection Pen is an essential step for adults managing type 2 diabetes. Building on the starter dose, it delivers reliable blood sugar control, meaningful weight support, and long-term metabolic health improvements. With once-weekly dosing and proven clinical results, Mounjaro 5 mg helps patients take control of their diabetes management and overall well-being.